A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas

This study is open to adults with advanced cancer of the colon, rectum, stomach, or pancreas, that is the cancer cannot be removed by surgery or has spread. People can take part in this study if their previous treatment was not successful, or no other treatment exists. The study aims to find the highest dose for the study medicine called BI 765049 that people with advanced cancer can tolerate. Another purpose is to find the most suitable dose and best way of administration of BI 765049 for further clinical development. BI 765049 may help the immune system fight cancer. Participants receive B

Trial Details

NCT ID
NCT06882746
Phase
PHASE1
Sponsor
Boehringer Ingelheim
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • BI 765049
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Hackensack, New Jersey, United States|40.88593,-74.04347

Key Eligibility Criteria

  • For all patients, signed and dated informed consent form (ICF)2/main ICF describing the study in accordance with International Council on Harmonisa…
  • Patient must be ≥18 years of age and at least at the legal age of consent in countries where it is greater than 18 years at the time of signature o…
  • In US: Patients with a histologically or cytologically confirmed diagnosis of colorectal carcinoma (CRC), gastric carcinoma (GC), or pancreatic duc…
  • In Europe: Patients with a histologically or cytologically confirmed diagnosis of CRC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →